UDCA plus phenobarbital safe, effective for infant cholestasis
Combined treatment with phenobarbital and ursodeoxycholic acid (UDCA) is superior to phenobarbital alone at treating cholestasis symptoms, and does so at a faster rate,…
Cholestasis
Recurrent ICP linked to condition’s severity in 1st pregnancy
Nearly one in three patients diagnosed with intrahepatic cholestasis of pregnancy (ICP) during a first pregnancy will develop the condition again in a subsequent…
Researchers develop mutation database, mouse model for PFIC2
Researchers have developed a database of all ABCB11 mutations known to cause progressive familial intrahepatic cholestasis type 2 (PFIC2) and a new mouse model…
New MYO5B gene mutation detected in man with PFIC type 10
A combination of two mutations in the MYO5B gene, including one that has not been previously reported, was the likely cause of a mild form…
ICP linked to lower levels of vitamin K in small study
Women with intrahepatic cholestasis of pregnancy (ICP), the most common liver complication during pregnancy, are significantly more likely to have reduced blood levels of…
In one year of writing about PFIC, I’ve been keeping secrets
It’s been over a year since I started writing this column about my family’s experience with progressive familial intrahepatic cholestasis (PFIC), and it’s been…
New mutation likely cause of PFIC type 1 in siblings with liver failure
A novel mutation in the ATP8B1 gene was the likely cause of progressive familial intrahepatic cholestasis (PFIC) type 1 in two siblings in India…
ACER3 enzyme may be therapeutic target in cholestasis: Lab study
ACER3, an enzyme involved in the metabolism of fat-like signaling molecules known as ceramides, plays a detrimental role in cholestasis-related liver damage — and,…
Cilnidipine, bexarotene ease liver damage in rat model of cholestasis
Preventive treatment with cilnidipine and bexarotene significantly reduced markers of inflammation, liver damage, and oxidative stress, a type of cellular damage, in a rat model…
RTY-694 shows promise in models of liver, bile duct diseases PFIC, PSC
An experimental oral therapy by Rectify Pharmaceuticals called RTY-694 reduced markers of slowed bile flow and inflammation in a mouse model of progressive…
